Phaseline

Targets › LY6G6D

LY6G6D (Lymphocyte antigen 6 complex locus protein G6d): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2029.

Open in Phaseline: the race on LY6G6D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cartography BiosciencesCBI-1214
Bispecific T cell engager targeting LY6G6D on colorectal cancer cells and CD3 on T cells
LY6G6D, CD3Phase 1Colorectal CancerApr 2029

Conditions

Colorectal Cancer (1)

Modalities

protein or peptide (1)

Companies

Cartography Biosciences (1)

Related targets

CD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.